May 2018

New Product - Vosevi

Vosevi (sofosbuvir/velpatasvir/voxilaprevir) is a fixed dose combination tablet containing the active substances sofosbuvir, velpatasvir and voxilaprevir. Sofosbuvir is a pan-genotypic inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, which is essential for viral replication. Velpatasvir is a pan-genotypic HCV inhibitor targeting the HCV NS5A protein, which is essential for both RNA replication and the assembly of HCV virions. Voxilaprevir is a pan-genotypic inhibitor of the NS3/4A protease. Vosevi is indicated for the treatment of chronic HCV infection in adults, without cirrhosis or with compensated cirrhosis, who have: genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor; genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor. Vosevi is contraindicated with rifampicin and rosuvastatin. Vosevi (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg) tablets are available in packs of 28.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia┬áPty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au